← Eichor
Study identifier: NCT07357298 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Condition: Breast Cancer  ·  Sponsor: H. Lee Moffitt Cancer Center and Research Institute

PhasePhase 3
Planned participants156
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This randomized, multi-institutional phase III trial evaluates whether routine surveillance brain MRI every 6 months improves detection and treatment characteristics of brain metastases in neurologically asymptomatic patients with stage IV breast cancer. Patients are stratified by receptor subtype, age, prior therapy, and study site, then randomized 1:1 to either scheduled surveillance MRIs or standard-of-care symptom-triggered imaging. The study aims to determine whether earlier detection leads to differences in treatment modality, frequency of brain metastases, leptomeningeal disease incidence, quality of life, and survival outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Rheese McNab  ·  813-745-1780  ·  Rheese.McNab@moffitt.org

Always discuss trial participation with your own doctor first.

Locations (2)

Baptist Health South FloridaMiami, Florida, United StatesNot Yet Recruiting
Moffitt Cancer CenterTampa, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07357298